Original news and analysis on international IP policy
From changes in policymaking leadership and staffing shake-ups to a flurry of hiring in law firms and new strategic alliances, the past few months have been an interesting time for IP people watching. With over 40 news items and over 80 names, here’s a substantial update on who’s who across governments, nonprofit organisations, and the private sector.
The launch of a study co-edited by the World Trade Organization, World Health Organization, and World Intellectual Property Organization on the intersection between public health, intellectual property and trade drew a full attendance from a wide array of stakeholders on 5 February.
After years of unsuccessful negotiations between nations, the World Trade Organization Dispute Settlement Body today gave Antigua and Barbuda the right to impose sanctions against the United States for blocking online gambling. The US was found in violation of WTO rules in 2007 and has failed to resolve the issue, so the Caribbean nation was given the right to retaliate in an area that is likely to force a US response - lifting US intellectual property rights.
What will 2013 bring for international intellectual property and innovation policy?
In the coming Intellectual Property Watch series for subscribers, our expert writers take a look at the top global policy issues and events in copyright, public health, legal battles, food security/biotech/biodiversity, trade, development, internet governance and more.
As 2012 becomes a memory, it is fair to say that the intellectual property rights discussion shifted over the past year, with trade agreements, over-reaching in copyright and patents, and the provision of technical assistance all falling under increased pressure. At least if the most-read Intellectual Property Watch stories of the year are any indication.
Washington, DC - United States attachés stationed around the world in order to promote intellectual property rights reported on their activities to US industry here last week. And the attachès posted in Geneva had strong words for the work of non-governmental organisations operating at the World Trade Organization and the United Nations agencies.
World Trade Organization negotiations to establish a multilateral register of geographical indications continue to be stalled over whether talks should apply only to wines and spirits as mandated, or can extend to other products and include talks on disclosure of origin in genetic material, the negotiations chair reported to the WTO Trade Negotiations Committee (TNC) today. He suggested a slightly different approach in the coming year.
During the joint news conference held in Paris on 27 November by Russian Prime Minister Dmitry Medvedev and French Prime Minister Jean-Marc Ayrault, Medvedev was asked a question of legislative scrutiny with regard to internet regulation in Russia. In his reply, the Russian prime minister admitted that the current legislation regulating the internet is “imperfect” and called upon the international community to “consider parameters to regulate the operation of the internet on the national or international level.”
The World Trade Organization Dispute Settlement Body yesterday heard arguments by parties in a dispute about Australia's new public health law requiring tobacco imports to be in plain packaging as a way to discourage tobacco use. Honduras presented a challenge to the Australian law, saying it is not in line with WTO rules on intellectual property rights, while Australia said it is a "sound, well-considered" action in the name of public health.
Richard Elliott writes: Canada’s Access to Medicines Regime (CAMR) was a unanimous pledge by Parliament to help people dying in developing countries because they lack access to affordable medicines. So far, it has delivered only one medicine to one country since Parliament created it more than 8 years ago (in May 2004). CAMR is clearly not working; it needs to be reformed to address the unnecessary deficiencies and limitations that have rendered it cumbersome and user-unfriendly for both developing countries and the manufacturers of lower-cost, generic medicines - the two parties that need to make use of CAMR if patients are to get the medicines they need.